Holen Sie sich die Stockscreener-App
3.8818
2.74%
0.0518
Schlusskurs vom Vortag:
$3.83
Offen:
$3.86
24-Stunden-Volumen:
4,277
Relative Volume:
0.00
Marktkapitalisierung:
$20.97M
Einnahmen:
$15.66M
Nettoeinkommen (Verlust:
$5.83M
KGV:
-0.1625
EPS:
-23.8939
Netto-Cashflow:
$466.20K
1W Leistung:
-14.46%
1M Leistung:
-17.85%
6M Leistung:
-41.27%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.86
$3.945
1-Wochen-Bereich:
$3.83
$4.61
52-Wochen-Spanne:
$2.90
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Firmenname
Neuphoria Therapeutics Inc
Sektor
Branche
Telefon
781-439-5551
Adresse
100 SUMMIT DR, BURLINGTON
Vergleichen Sie NEUP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.90 | 20.60M | 15.66M | 5.83M | 466.20K | -23.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.29 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.07 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
849.51 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.01 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
199.95 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Bestätigt | Maxim Group | Buy |
| 2022-01-10 | Eingeleitet | Berenberg | Buy |
| 2022-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Eingeleitet | Evercore ISI | Outperform |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Neuphoria Therapeutics Inc Aktie (NEUP) Neueste Nachrichten
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Neuphoria Therapeutics (NASDAQ:NEUP) Cut to Strong Sell at Zacks Research - Defense World
Abeona Therapeutics (NASDAQ:ABEO) and Neuphoria Therapeutics (NASDAQ:NEUP) Critical Comparison - Defense World
Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees - Yahoo Finance
ISS recommends shareholders vote for Neuphoria’s board nominees By Investing.com - Investing.com India
Institutional Shareholder Services Recommends Shareholders of Neuphoria to Vote for its Director Nominees - marketscreener.com
ISS recommends shareholders vote for Neuphoria’s board nominees - Investing.com
Neuphoria Therapeutics (NEUP) Gains ISS Support for Director Nom - GuruFocus
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees - The Manila Times
HC Wainwright Has Lowered Expectations for Neuphoria Therapeutics (NASDAQ:NEUP) Stock Price - Defense World
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA) - The Globe and Mail
Neuphoria Therapeutics (NEUP) Stock Analysis Report | Financials & Insights - Benzinga
HC Wainwright & Co. Maintains Neuphoria Therapeutics (NEUP) Buy Recommendation - Nasdaq
NEUP: Analyst Lowers Price Target by 66% but Maintains 'Buy' Rat - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer By Investing.com - Investing.com Nigeria
Will Neuphoria Therapeutics Inc. stock deliver strong dividend growthIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Neuphoria Therapeutics (NEUP) Considers Strategic Alternatives A - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer - Investing.com
Neuphoria responds to Lynx1's revised indication of interest at a reduced price and premium - marketscreener.com
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium - The Manila Times
Is Neuphoria Therapeutics Inc. stock near bottom after declineEarnings Risk Report & Weekly Top Stock Performers List - Newser
Lynx1 Master Sends a Letter to the Shareholders of Neuphoria Therapeutics - marketscreener.com
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders - Yahoo Finance
Lynx1 Master Fund Critiques Neuphoria Therapeutics Inc. Board's Capital-Raising Strategy and Proposes Independent Director Nominees in Proxy Statement - marketscreener.com
Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program - MSN
Neuphoria responds to Lynx1’s proxy contest claims in board dispute By Investing.com - Investing.com Australia
Neuphoria Therapeutics (NEUP) Encourages Shareholders to Support Its Nominees - GuruFocus
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions - The Manila Times
Neuphoria responds to Lynx1’s proxy contest claims in board dispute - Investing.com
Neuphoria Therapeutics downgraded to Neutral from Buy at Lucid Capital - MSN
Reviewing Neuphoria Therapeutics (NEUP) & The Competition - Defense World
What analysts say about Neuphoria Therapeutics Inc stockMACD Histogram Signals & Discover Your Financial Freedom Formula - earlytimes.in
Sell Signal: How Neuphoria Therapeutics Inc. stock reacts to global recession fearsSwing Trade & Free AI Powered Buy and Sell Recommendations - moha.gov.vn
Lynx1 Capital Management Solicits Proxies from Shareholders of Neuphoria Therapeutics - marketscreener.com
Would You Still Hold Neuphoria Therapeutics Stock If It Fell Another 30%? - Trefis
Neuphoria urges stockholders to vote for its nominees amid strategic review - Investing.com Nigeria
Neuphoria Therapeutics Sends Letter to Stockholders - marketscreener.com
Neuphoria Therapeutics (NEUP) Outlines Strategic Review Ahead of Annual Meeting - GuruFocus
Making the Most of Varied Backgrounds: Ogunbufunmi’s Bold Move Toward Technology Leadership - Bitget
Neuphoria urges stockholders to vote for its nominees amid strategic review By Investing.com - Investing.com South Africa
Neuphoria Therapeutics Inc. Sends Letter to Stockholders - Yahoo Finance
Finanzdaten der Neuphoria Therapeutics Inc-Aktie (NEUP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):